24 citations
,
January 2010 in “Annales d'endocrinologie”
This review discusses treatment options for hirsutism in women of childbearing age, focusing on the use of contraceptives, CPA, spironolactone, and third-line therapies, and reports no clinical results.
5 citations
,
January 1984 in “Journal of psychosomatic obstetrics and gynecology/Journal of psychosomatic obstetrics and gynaecology”
This study found that treatment with cyproterone acetate and ethinylestradiol in hirsute women reduced testosterone and androstenedione levels, decreased hair growth, and increased cortisol levels without changing catecholamine excretion.
26 citations
,
January 1994 in “Hormone and Metabolic Research”
This study found that one year of antiandrogen treatment with spironolactone significantly decreased bone mineral density in young women with androgen excess.
150 citations
,
February 2008 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”
This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.
38 citations
,
October 1996 in “Dermatologic Clinics”
This review discusses inflammatory and medication-related skin conditions associated with kidney disease and emphasizes the importance of timely referral to nephrology, reporting no new clinical results.
The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.
The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.
The conversation is about adding a topical anti-androgen to a hair loss treatment regimen that includes dutasteride and oral minoxidil. The user is considering topical finasteride or dutasteride, Nizoral shampoo, KX-826, and topical spironolactone, while avoiding RU58841 due to safety concerns.
The conversation discusses hair loss treatments, including dutasteride, oral minoxidil, finasteride, and potential additions like topical finasteride, minoxidil, micro-needling, and topical anti-androgens such as RU58841. The effectiveness and worth of these treatments, including localized dutasteride mesotherapy, are considered.
The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.
Can pyrilutamide be used by both men and women, or only in specific cases?Pyrilutamide (KX-826) is an investigational topical anti-androgen that has been trialled in both men and women, but it is not approved for hair loss anywhere; the company reports that its China Phase III trial in men met its primary endpoint, but the data come from sponsor announcements rather than peer-reviewed journals, and long-term safety is unknown.
What is pyrilutamide, and how does it help with androgenic alopecia or hair loss caused by DHT?Pyrilutamide (KX-826) is an investigational topical antiandrogen designed to block DHT at the androgen receptor in the scalp rather than lower DHT in the blood. Its sponsor has announced positive Phase III top-line results in China, but none of the data are peer-reviewed and it is not approved as a medicine anywhere.